Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

v2.4.1.9
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)
In Thousands, unless otherwise specified
 9 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Cash flows from operating activities:    
Net loss $ (3,388)us-gaap_NetIncomeLoss $ (2,363)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock based compensation expense 365us-gaap_ShareBasedCompensation 272us-gaap_ShareBasedCompensation
Fair value adjustment of common stock warrants 0us-gaap_FairValueAdjustmentOfWarrants (10)us-gaap_FairValueAdjustmentOfWarrants
Depreciation 30us-gaap_DepreciationDepletionAndAmortization 24us-gaap_DepreciationDepletionAndAmortization
Amortization of intangible assets 156us-gaap_AmortizationOfIntangibleAssets 156us-gaap_AmortizationOfIntangibleAssets
Accrued interest on convertible promissory note (21)us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet (25)us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet
Deferred taxes (62)us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization (61)us-gaap_IncomeTaxReconciliationNondeductibleExpenseAmortization
Accrued interest on promissory note payable 16us-gaap_IncreaseDecreaseInInterestPayableNet 4us-gaap_IncreaseDecreaseInInterestPayableNet
Changes in operating assets and liabilities:    
Accounts receivable 101us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables 195us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables
Prepaid expenses and other current assets 17us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (62)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Deferred financing costs 162us-gaap_IncreaseDecreaseInDeferredCharges (129)us-gaap_IncreaseDecreaseInDeferredCharges
Accounts payable and accrued expenses 39us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities 133us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
Accrued compensation 36clrx_IncreaseDecreaseInAccruedCompensation 67clrx_IncreaseDecreaseInAccruedCompensation
Deferred revenue (36)us-gaap_IncreaseDecreaseInDeferredRevenue 0us-gaap_IncreaseDecreaseInDeferredRevenue
Current assets and liabilities from discontinued operations, net (5)clrx_IncreaseDecreaseInCurrentAssetsAndLiabilitiesFromDiscontinuedOperations 143clrx_IncreaseDecreaseInCurrentAssetsAndLiabilitiesFromDiscontinuedOperations
Net cash used in operating activities (2,590)us-gaap_NetCashProvidedByUsedInOperatingActivities (1,656)us-gaap_NetCashProvidedByUsedInOperatingActivities
Cash flows from investing activities:    
Acquisition of property and equipment (17)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (17)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Net cash used in investing activities (17)us-gaap_NetCashProvidedByUsedInInvestingActivities (17)us-gaap_NetCashProvidedByUsedInInvestingActivities
Cash flows from financing activities:    
Proceeds from at-the-market facility 23us-gaap_ProceedsFromStockPlans 0us-gaap_ProceedsFromStockPlans
Proceeds from sale of common stock, net of expenses of $480 1,347us-gaap_ProceedsFromIssuanceOfCommonStock 0us-gaap_ProceedsFromIssuanceOfCommonStock
Net cash provided by financing activities 1,370us-gaap_NetCashProvidedByUsedInFinancingActivities 0us-gaap_NetCashProvidedByUsedInFinancingActivities
Net decrease in cash and cash equivalents (1,237)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (1,673)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents, beginning 1,430us-gaap_CashAndCashEquivalentsAtCarryingValue [1] 4,039us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents, ending 193us-gaap_CashAndCashEquivalentsAtCarryingValue 2,366us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplemental disclosure of non-cash activities:    
Shares issued in CollabRx acquisition 0us-gaap_StockIssued1 932us-gaap_StockIssued1
Note receivable used as consideration for CollabRx acquisition 0us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1 300us-gaap_NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1
Promissory Note issued in CollabRx acquisition 0us-gaap_NotesIssued1 500us-gaap_NotesIssued1
Fair value of assets acquired in CollabRx acquisition 0us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1 2,253us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
Liabilities assumed in CollabRx acquisition $ 0us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 $ 997us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
[1] Derived from the Company's audited consolidated financial statements.